Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 4Recurrence 3Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × Automobiles × Clear all
NCT05852717 2026-05-06

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Hoosier Cancer Research Network

Phase 2 Recruiting
32 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04089215 2023-11-24

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 2 Unknown
82 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04718883 2023-11-24

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 2 Active not recruiting
59 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡